The Harvard Clinical Research Institute expanded its 20,000-patient, four-year dual antiplatelet therapy study into seven European countries.

The "DAPT Study" is investigating 12- and 30-month periods of therapy for drug-eluting stent recipients. After the a percutaneous coronary intervention , patients take a combination of aspirin and a thienopyridine antiplatelet medication to reduce the risk of blood clots.